← WeSearch · Blindspots

Full coverage · not a ranking

Innovent Biologics Surges After Signing Up to $10.5 Billion Deal With Pfizer - Morningstar

First seen May 28, 2026, 8:14 PM · latest May 28, 2026, 11:01 PM · free · no behavioral personalization

3Articles in sample

3Distinct publishers

0Wire-service items

0High-fact publishers

3 distinct publishers, one article each in this sample.

Ownership mix: Other: 3

What happened

Innovent Biologics rose as much as 10%, after entering a strategic global licensing and collaboration agreement with Pfizer to develop oncology medicines.

3 publishers · 3 articles · switch to 1-minute for disagreement and framing.

What happened

Innovent Biologics rose as much as 10%, after entering a strategic global licensing and collaboration agreement with Pfizer to develop oncology medicines.

Why the coverage differs

AI-assisted comparison · labeled · generated Jun 8, 2026, 4:30 AM · not a verdict

What happened: Innovent Biologics shares rise 10% after pact with Pfizer of up to $10.5 billion

Where coverage diverges: Center: 3 (CNBC — Top, South China Morning Post, Google News).

Comparison summary

AI-assisted · Cerebras / Llama · Jun 8, 2026, 4:30 AM · inspect sources below rather than trusting this alone

What happened: Innovent Biologics shares rise 10% after pact with Pfizer of up to $10.5 billion

Where coverage diverges: Center: 3 (CNBC — Top, South China Morning Post, Google News).

What's missing: AI bias-comparison is temporarily offline. Configure Cerebras in admin to enable rich comparison summaries.

How to read these numbers

Article count is not confirmation count. Wire rewrites and same-outlet follow-ups inflate totals. Prefer distinct publishers and primary links on each story page.

Report timeline

Oldest → newest among clustered members. Gaps may mean delayed pickup, not silence.

May 28, 2026, 8:10 PM

CNBC — Top · Center
Innovent Biologics shares rise 10% after pact with Pfizer of up to $10.5 billion
May 28, 2026, 10:29 PM

South China Morning Post · Center
China’s Innovent Biologics signs US$10.5 billion Pfizer deal for 12 cancer drug trials
May 28, 2026, 10:51 PM

Google News · Center
Innovent Biologics Surges After Signing Up to $10.5 Billion Deal With Pfizer - Morningstar

Coverage by perspective

Perspective labels are external consensus ratings (AllSides / Ad Fontes / MBFC-style), not WeSearch truth scores. Center is not automatically more accurate.

Center · 3

Google News Center

Innovent Biologics Surges After Signing Up to $10.5 Billion Deal With Pfizer - Morningstar

Comprehensive up-to-date news coverage, aggregated from sources all over the world by Google News.

Mixed Factuality · Other

South China Morning Post Center

China’s Innovent Biologics signs US$10.5 billion Pfizer deal for 12 cancer drug trials

The agreement covers eight early-stage trials from Innovent and four discovery programmes from global giant Pfizer.

Mixed Factuality · Other

CNBC — Top Center

Innovent Biologics shares rise 10% after pact with Pfizer of up to $10.5 billion

Innovent Biologics rose as much as 10%, after entering a strategic global licensing and collaboration agreement with Pfizer to develop oncology medicines.

Mixed Factuality · Other

Headline framing

Vocabulary fingerprints · not a political endorsement

AI framing analysis temporarily offline. Configure Cerebras in admin to enable framing comparison.

Per-source framing

Center

CNBC — Top

Innovent Biologics shares rise 10% after pact with Pfizer of up to $10.5 billion

Center angle.

Center

South China Morning Post

China’s Innovent Biologics signs US$10.5 billion Pfizer deal for 12 cancer drug trials

Center angle.

Center

Google News

Innovent Biologics Surges After Signing Up to $10.5 Billion Deal With Pfizer - Morningstar

Center angle.

Bias/ownership: published methodology on source profiles · AI text always labeled · no reader paywall · no engagement ranking of news · transparency · contribute Ws · home